Table of Content

 1. Executive Summary

     
    Executive Summary
        Key Findings
        Key Questions this Study will Answer
        Big Market Themes
        M&A Stakeholder Opportunity Heat Map
        Major Growth Opportunities
        Strategic Imperatives for the Life Sciences Industry

 2. Research Scope and Assumptions

     
    Research Scope and Assumptions
        Scope and Segmentation
        Methodology and Assumptions
        Methodology and Assumptions (continued)

 3. Market Dynamics

     
    Market Dynamics
        Regulatory and Legislative Changes Impacting M&A
        Non-Traditional Players—Infusing Competition into Traditional Markets
        FAMGA* M&A Activity—Comparison with Traditional Healthcare Players
        Growing PE Ownership in the Healthcare Space
        Growing PE Ownership in the Healthcare Space (continued)

 4. Market Overview

     
    Market Overview
        Healthcare M&A Activity
        Geographic Distribution of Targets
        Market Attractiveness for M&A
        Notable M&A Deals
        Active Participants in the M&A Landscape

 5. Market Overview—Pharma and Biopharma

     
    Market Overview—Pharma and Biopharma
        Pharma and Biopharma M&A Activity
        Factors Impacting M&A
        Roche Case Study—M&A to Create End-to-End Precision Medicine Portfolio
        Activity Profile of Top 10 Pharma Companies
        Connected Health—From Patient Communication to Engagement
        Growth Opportunity 1—Patient Engagement 2.0
        Pharmaceutical Companies Can Engage Patients Throughout the Drug Discovery and Development Cycle
        Emerging M&A Opportunity Areas

 6. Market Overview—Contract Service Organizations (CRO and CDMO)

     
    Market Overview—Contract Service Organizations (CRO and CDMO)
        CRO Industry M&A Activity
        Eurofins Scientific Case Study—M&A Story of an Emerging Competitor
        Activity Profile of Top 10 CRO Companies
        Clinical Trial Recruitment and Retention Challenge for CROs
        Growth Opportunity 2—Clinical Trial Recruitment and Retention
        CDMO Industry M&A Activity
        Thermo Fisher and Patheon—Redefining One-stop-shop
        Activity Profile of Top 10 CDMO Companies
        Will M&A Address the Size Challenge?
        Growth Opportunity 3—Cell and Gene Therapy

 7. Market Overview—Diagnostic and Research Tools

     
    Market Overview—Diagnostic and Research Tools
        DRT Industry M&A Activity
        Factors Impacting M&A
        Invitae Case Study—Genetic Information Company
        Activity Profile of Top 10 DRT Companies
        A Very Active PE Landscape—Increasing Valuations
        Rising Valuations—A New Challenge for M&A
        Growth Opportunity 4—Insight-as-a-Service

 8. Concluding Thoughts

     
    Concluding Thoughts
        Concluding Thoughts
        Top 3 Predictions
        Legal Disclaimer

 9. Appendix

     
    Appendix
        M&A and Collaboration Drivers
        Top Technologies Attracting PE Investment
        Collaboration Assessment
        Collaboration Assessment (continued)
        Collaboration Assessment (continued)
        Collaboration Assessment (continued)
        Collaboration Assessment (continued)
        List of Exhibits
        List of Exhibits (continued)